Synapse - Population Sciences Research Program

Results (14)

Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay

Meeting Abstract

Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
Blood (2014)

Fulltext@MSK | Save

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
Blood (2013)

Fulltext@MSK | Save

Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant

Meeting Abstract

Moskowitz, A. J.; Hamlin, P. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M.; Meikle, J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Blood (2009)

Fulltext@MSK | Save

The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders

Meeting Abstract

Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save